BioWa的Potelligent技朮获得美国专利

BioWa's Potelligent technology, patented under U.S. 6,946,292, utilizes host cells engineered to lack fucosyltransferase, producing afucosylated monoclonal antibodies. This defucosylation enhances antibody-dependent cell-mediated cytotoxicity (ADCC) by in...